You have access
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202)
AYA KATO, NORIKATSU MIYOSHI, TORU OHTSURU, DAISUKE SAKAI, JUNICHI HASEGAWA, KEN NAKATA, MITSUNOBU IMASATO, TAKESHI KATO, MASAKAZU IKENAGA, TOSHIHIRO KUDO, MITSUYOSHI TEI, YOSHINORI KAGAWA, MAMORU UEMURA, HIDEKAZU TAKAHASHI, TAROH SATOH, MASAKI MORI, TSUNEKAZU MIZUSHIMA, HIROFUMI YAMAMOTO, KOHEI MURATA, YUICHIRO DOKI and HIDETOSHI EGUCHI
Anticancer Research April 2022, 42 (4) 1859-1865; DOI: https://doi.org/10.21873/anticanres.15662